Doctor Anywhere attracts US$40.8mil Series C to scale healthcare innovation

  • Growth fueled by rapid customer acquisition, product innovation & regional expansion
  • Funds will bolster healthcare innovation, expand company's footprint in secondary care

The team at Doctor Anywhere

Doctor Anywhere (DA), a Singapore-based tech-led healthcare company, has announced a US$40.8 million (RM190.5 million) Series C1 extension round with participation from Square Peg and Novo Holdings.

The influx of funds will strategically drive next-generation healthcare innovation within the company and deepen its presence in secondary care, according to a company statement.

DA plans to intensify efforts in product innovation, aiming to build a vertically integrated digital healthcare ecosystem. This ecosystem will cater to the rising demand for comprehensive and connected healthcare solutions, prioritising patient experiences and outcomes.

In the context of a global funding downturn, this fundraising serves as a testament to DA's robust performance and business model. The company attributes its growth momentum to rapid customer acquisition, continuous product innovation, regional expansion efforts, and the recent acquisition of a specialist healthcare group, Asian Healthcare Specialists. 

Tushar Roy, partner at Square Peg said, “Our continued investment underscores DA’s emergence as the dominant digital health platform across Southeast Asia."

Lim Wai Mun, founder & CEO of Doctor Anywhere noted the company’s success in building a regional digital healthcare ecosystem which delivers accessible, convenient healthcare services through digital innovation. He outlined the goal for the next phase of Southeast Asia's healthcare evolution, "To empower individuals to take charge of their health and well-being with early detection and preventive measures against chronic illnesses.  We are excited about the possibilities that Generative AI offers to advance this goal."

Dr. Amit Kakar, senior partner and head of Novo Holdings Asia, highlighted Novo's investment as being part of its commitment to fostering personalised and intuitive healthcare experiences for better health outcomes. "We firmly support DA’s vision to deliver patient-centric care through innovative technology."

DA claims its tech-driven approach has been a key differentiator, leading to innovations such as the industry's first online supervised tele-antigen rapid testing service. Building on this foundation and driven by its mission to deliver personalised, borderless, and inclusive healthcare regionally, the company aims to introduce new service offerings, strengthen strategic partnerships, and explore acquisition opportunities.


Related Stories :

Keyword(s) :
Author Name :
Download Digerati50 2020-2021 PDF

Digerati50 2020-2021

Get and download a digital copy of Digerati50 2020-2021